12/05/2026
ãWhat Really Determines the Outcome in IgA Nephropathy? A Doctor Breaks It Downã
IgA nephropathy (IgAN) is the most common primary glomerular disease in adults. But if youâve ever sat in a clinic waiting room, you might have noticed something surprising: two people with the same diagnosis can have completely different outlooks.
One patient stays stable for decades. The other progresses toward kidney failure within a few years.
Why the huge difference?
Itâs not luck. It comes down to four key indicators.
1. Proteinuria (Urine Protein) â The Most Critical Factor
Proteinuria is both a marker of kidney damage and a driver of disease progression.
< 0.5 g/24h â very low risk of kidney failure; considered stable.
0.5â1.0 g/24h â risk increases; active intervention is needed.
> 1.0 g/24h â kidney function may decline by 5â10% per year.
> 3.5 g/24h â up to 50% risk of kidney failure within 10 years.
Goal: Keep 24âhour urine protein below 0.5 g â the closer to zero, the better.
2. Blood Pressure â The Silent Accelerator
High blood pressure quietly damages the small arteries in the kidneys, speeding up fibrosis.
Target: < 130/80 mmHg (even lower if proteinuria is present)
Blood pressure sustained at âĨ 140/90 mmHg can double or triple the rate of kidney function decline.
Many patients say, âI donât feel it.â Thatâs exactly why itâs dangerous.
3. Baseline Kidney Function â Your Starting Point
The eGFR (estimated glomerular filtration rate) at diagnosis sets the stage.
eGFR âĨ 90 â excellent prognosis
eGFR 60â89 â early CKD stage; stable with good management
eGFR 30â59 â highârisk zone; requires tight control
eGFR < 30 â kidney failure risk rises sharply; dialysis planning may be needed
Your eGFR is not fixed â it can be preserved with proper treatment and lifestyle choices.
4. Kidney Biopsy â The True Picture
Pathology reveals what lab numbers canât. Three features matter most:
Percentage of glomerulosclerosis â more scarring means worse prognosis.
Crescents â indicate active, rapidly progressing damage that needs urgent treatment.
Interstitial fibrosis/tubular atrophy â irreversible damage; the more there is, the faster kidney function declines.
The milder the pathology, the safer you are. The more severe it is, the more aggressive the treatment needed.
How to Take Control â Practical Steps
1. Go all in on proteinuria control
Firstâline: ACE inhibitors or ARBs (e.g., losartan, irbesartan)
If proteinuria > 1 g/day, add SGLT2 inhibitors (e.g., dapagliflozin)
If > 3.5 g/day, discuss immunosuppressive therapy with your doctor
2. Keep blood pressure on target
Lowâsalt diet (â¤5 g/day)
ARBs/ACE inhibitors as the foundation; add other agents if needed
3. Protect your kidney function
Avoid NSAIDs, unverified herbs, and contrast dyes unless absolutely necessary
Prevent infections (colds, tonsillitis, gastroenteritis) â they can trigger IgAN flares
Get adequate rest; avoid excessive fatigue
4. Stay on a regular monitoring schedule
Every 1â3 months: urine protein, kidney function, blood pressure
Every 6â12 months: kidney ultrasound, immunological markers
Two Patients, Two Paths
Case 1 â Diagnosed at age 30 with eGFR 85, urine protein 0.3 g, normal blood pressure, mild pathology.
15 years later: eGFR 82, urine protein 0.2 g. Working, living normally.
Case 2 â Diagnosed at age 32 with eGFR 70, urine protein 3.2 g, BP 150/95, severe pathology.
Initially neglected treatment, stopped medications, poor diet.
2 years later: eGFR 35 â in the highârisk zone for kidney failure.
The Bottom Line
IgA nephropathy does not have a fixed destiny.
Your outcome is shaped by how well you manage proteinuria, blood pressure, baseline kidney function, and pathology.
Take your medications. Monitor your numbers. Protect your kidneys.
With good management, many people with IgAN live stable, full lives â sometimes without ever needing dialysis.
If you have recent lab results and want a clearer picture of your risk, consider sharing them with your nephrologist for a personalized plan.
